Live tape
Top 8, mentions 7d29,805NVDA14,700 mentions▲ +0.04ANT3,932 mentions▲ +0.06GOOGL2,871 mentions▲ +0.04SPY2,163 mentions▲ +0.05SPCX1,834 mentions▲ +0.07QQQ1,744 mentions▲ +0.04AMD1,367 mentions▲ +0.06AAPL1,194 mentions▲ +0.04

Equity · Healthcare

DNA

NYSE

Ginkgo Bioworks Holdings (DNA)

10.66 USD +6.55% vs prior close Sep 25, 2026
Ginkgo Bioworks Holdings, Inc. price graph
24 sessions
12 6 24 Aug 25 Sep

The line runs 7 USD on 24 August through 10.66 USD on 25 September, on a scale from 6 to 12. Days the market did not trade hold the previous close, flat.

Market cap
590.9M USD
Revenue, year to Dec 2025
170.2M USD
EPS, diluted, year to Dec 2025
−5.64 USD
52-week range
5 USD – 16.15 USD
Avg volume
77.1K

as of Sep 25, 2026

Have Ginkgo Bioworks Holdings (DNA) insiders bought or sold shares recently?

In the 90 days to 21 Nov 2026, Ginkgo Bioworks Holdings insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 16 Oct 2025, show no open-market purchase.

Form 4, 90 days to 21 Nov 2026, newest reported trade 19 Oct 2026

0buys
7sells
$1.38Mnet sold
4other filings
Have Ginkgo Bioworks Holdings (DNA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
19 Oct 2026Canton Barry10% OwnerSell41,172418K USD
19 Oct 2026Coen Steven P.See remarksSell7668K USD
19 Oct 2026Kelly Jason RSee remarksSell45,682463K USD
19 Oct 2026Shetty Reshma P.See remarksSell41,172418K USD
05 Oct 2026Coen Steven P.See remarksSell2,40336K USD
15 Sep 2026HENRY CHRISTIAN ODirectorSell5,00035K USD
24 Aug 2026Coen Steven P.See remarksSell3302K USD
Sold7 open-market sales136,525$1.38M
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Ginkgo Bioworks Holdings (DNA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
16 Oct 2026Canton Barry10% OwnerOption exercise76,462
16 Oct 2026Coen Steven P.See remarksOption exercise1,486
16 Oct 2026Kelly Jason RSee remarksOption exercise81,484
16 Oct 2026Shetty Reshma P.See remarksOption exercise76,462

Which funds hold Ginkgo Bioworks Holdings (DNA)?

9 of the 45 institutional funds we track reported a Ginkgo Bioworks Holdings position for the quarter ended 30 Sep 2026 — a combined 76.9M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Ginkgo Bioworks Holdings (DNA)?
FundPositionSharesValueShares q/q
Viking Global InvestorsHeld (±25%)2,900,02537.2M USD−18.9%
D. E. Shaw & Co.Added912,34711.7M USD+502.8%
Renaissance TechnologiesHeld (±25%)637,0538.2M USD+18.0%
Millennium ManagementHeld (±25%)559,4787.2M USD−12.4%
Tudor Investment CorpHeld (±25%)399,6145.1M USD+19.0%
AQR Capital ManagementTrimmed242,2113.1M USD−61.0%
Citadel AdvisorsAdded218,7242.8M USD+67.0%
Man GroupAdded108,8991.4M USD+349.8%
Two Sigma InvestmentsTrimmed18,917243K USD−68.7%
Marshall WaceExited

Ginkgo Bioworks Holdings (DNA) US federal contracts

US federal agencies committed 28.8M USD in contracts to Ginkgo Bioworks Holdings (DNA) in fiscal 2026, the year to 30 Sep 2026, against 4.0M USD the year before.

USAspending.gov

28.8MUSDfiscal 2026
4.0MUSDfiscal 2025
67.2MUSDfiscal 2024
Ginkgo Bioworks Holdings (DNA) US federal contracts
SignedAgencyContractCommitted
03 May 2026Centers for Disease Control and PreventionDepartment of Health and Human ServicesMETAGENOMIC NEXT-GENERATION SEQUENCING (MNGS)REFERENCE LABORATORY TESTING · 75D30126F000043.2M USD
17 Jan 2025Centers for Disease Control and PreventionDepartment of Health and Human ServicesTRAVELER-BASED GENOMIC SURVEILLANCE PROGRAMSUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT · 75D30125C2043978.0M USD
15 Jan 2025Centers for Disease Control and PreventionDepartment of Health and Human ServicesTEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30125F00003450K USD
27 Sep 2024Centers for Disease Control and PreventionDepartment of Health and Human ServicesTEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30124F00002775K USD
06 Sep 2024Centers for Disease Control and PreventionDepartment of Health and Human ServicesTEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30124F000013.8M USD
26 Aug 2024Centers for Disease Control and PreventionDepartment of Health and Human ServicesTRAVELER-BASED GENOMIC SURVEILLANCESUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT · 75D30124C198951.2M USD
29 Jan 2024Defense Advanced Research Projects AgencyDepartment of DefenseDARPA ICE CONTROL FOR COLD ENVIRONMENTS (ICE)NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; APPLIED RESEARCH · HR001124C03785.2M USD
02 May 2023Department of the NavyDepartment of DefenseDNA RECORDING INTRINSIC CELLULAR BIOINTELLIGENCE (DRINC BIO)GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH · N6600123C45091.8M USD
15 Dec 2022Department of the ArmyDepartment of DefenseDARPA CONTRACT AWARD (BASE) "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS"GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH · W911NF23C00024.8M USD
16 Aug 2022Centers for Disease Control and PreventionDepartment of Health and Human ServicesAIRPORT GENOMIC TESTINGSPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL · 75D30122C1493362.6M USD

Contracts of US$100,000 or more signed since April 2022; the amount is what the government has committed so far, which grows when options are exercised. Defense Department contracts are published about 90 days after signing, so the latest year is still filling in.

What has been filed or recorded for Ginkgo Bioworks Holdings (DNA)?

The filings we hold for Ginkgo Bioworks Holdings, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 19 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Ginkgo Bioworks Holdings (DNA)?
And
19 Oct 2026Fails to deliverShares failed to deliver1,943 shares20K USD notional · 0.004% of shares out
13 Oct 2026Fails to deliverShares failed to deliver4,934 shares58K USD notional · 0.009% of shares out
08 Oct 2026Fails to deliverShares failed to deliver18,216 shares209K USD notional · 0.033% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedRevenue $28M
30 Sep 2026FinancialsTotal assets944.5M USDat period end
30 Sep 2026FinancialsTotal equity392.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedRevenue $20M
31 Mar 2026Quarterly earningsQ1 2026 reportedRevenue $19M
31 Dec 2025Annual reportFY 2025 reportedEPS −5.64 USDRevenue $170M
31 Dec 2025FinancialsRevenue170.2M USDfiscal year
31 Dec 2025FinancialsNet income−312.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−5.64 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.45 USDRevenue $29M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.10 USDRevenue $39M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.68 USDRevenue $38M
31 Dec 2024Annual reportFY 2024 reportedEPS −10.54 USDRevenue $227M

What do people ask about Ginkgo Bioworks Holdings (DNA)?

From live data
What did Ginkgo Bioworks Holdings shares close at?10.66

Ginkgo Bioworks Holdings closed at 10.66 USD on 25 Sep 2026, up 6.55% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Ginkgo Bioworks Holdings’ market cap?590.9M

Ginkgo Bioworks Holdings is worth 590.9M USD by market value as of 25 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Ginkgo Bioworks Holdings’ revenue?170.2M

Ginkgo Bioworks Holdings reported revenue of 170.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Ginkgo Bioworks Holdings insiders bought or sold shares recently?7 sales

In the 90 days to 21 Nov 2026, Ginkgo Bioworks Holdings insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 16 Oct 2025, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Ginkgo Bioworks Holdings?9 of 45

9 of the 45 funds we track reported a Ginkgo Bioworks Holdings position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, D. E. Shaw & Co. and Renaissance Technologies. See Funds

When did Ginkgo Bioworks Holdings last report earnings?

Ginkgo Bioworks Holdings last reported earnings on 30 Sep 2026 for Q3 2026; no next date is announced in SEC filings yet. See Filings

Does Ginkgo Bioworks Holdings have government contracts?28.8M

Yes. US federal agencies committed 28.8M USD in contracts to it in fiscal 2026, the year to 30 Sep 2026 (USAspending.gov). See Contracts

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. USAspendingUSAspending.gov (U.S. Department of the Treasury), federal prime contract awards
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings
  10. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words